Results 81 to 90 of about 5,685 (219)

Co-administration of iloprost and eptifibatide in septic shock (CO-ILEPSS)—a randomised, controlled, double-blind investigator-initiated trial investigating safety and efficacy

Critical Care, 2019
BackgroundPart of the pathophysiology in septic shock is a progressive activation of the endothelium and platelets leading to widespread microvascular injury with capillary leakage, microthrombi and consumption coagulopathy.
R. Berthelsen, S. Ostrowski, M. Bestle, P. Johansson   +3 more
semanticscholar   +1 more source

A Critical Review on BH3 Mimetic Drugs and the Treatment of Cancer‐Associated Thrombosis (CAT): A Proposed Design for a Drug Delivery System Capable of Simultaneously Targeting Tumor Cells and Activated Platelets

Cancer Medicine, Volume 14, Issue 18, September 2025.
Targeting Cancer associated thrombosis (CAT): The left panel (A) shows cancer‐associated thrombosis with activated platelets expressing αIIbβ3 in close contact with tumoral vasculature expressing αvβ3 integrin, where both cells release a significant amount of thrombin.
Mehran Ghasemzadeh, Nazanin Heidari, Jalal Naghinezhad, Alireza Ghasemzadeh, Ehteramolsadat Hosseini   +4 more
wiley   +1 more source

Comparison between Intracoronary Abciximab and Intravenous Eptifibatide Administration during Primary Percutaneous Coronary Intervention of Acute ST-Segment Elevation Myocardial Infarction

Journal of Tehran University Heart Center, 2015
Background: Administration of glycoprotein IIb/IIIa inhibitors is an effective adjunctive treatment strategy during primary percutaneous coronary intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI).
MohammadHasan Namazi, Morteza Safi, Hosein Vakili, Habibollah Saadat, Esfandiar Karimi, Ramin Khameneh-Bagheri   +5 more
doaj  

Platelet aggregation inhibition by Eptifibatide versus high dose Tirofiban during primary percutaneous interventions

The Egyptian Heart Journal, 2014
Background: Platelet aggregation occurs as a central role in acute coronary syndrome (ACS), and glycoprotein GP IIb/IIIa inhibitors may enhance the benefits expected from early recanalisation. Aim: To compare the degree of platelet aggregation inhibition
Yasser Sadek Nassar, Mohamed Laimud, Mohamed Afify, Mohamed Ashraf Shawky   +3 more
doaj   +1 more source

Glycoprotein IIb/IIIa Receptor Inhibitors in Patients with ST-Segment Elevation Myocardial Infarction and Primary Percutaneous Coronary Intervention

Рациональная фармакотерапия в кардиологии, 2020
Recently, there has been a positive trend to reduce mortality from myocardial infarction. One of the reasons for such dynamics is the development of angiographic service in our country and the increase in the number of primary percutaneous coronary ...
A. S. Tereshchenko, Е. V. Merkulov, A. M. Samko   +2 more
doaj   +1 more source

Evaluation of CYP2C19 Clinical Decision Support Alerts to Guide P2Y12 Inhibitor Prescribing

Clinical Pharmacology &Therapeutics, Volume 118, Issue 2, Page 470-479, August 2025.
P2Y12 inhibitor selection involves numerous factors, including CYP2C19 genetics, since evidence demonstrates reduced clopidogrel efficacy in patients with decreased or no function CYP2C19 variants. In 2020, Indiana University health embedded interruptive clinical decision support (CDS) alerts in the electronic health record (EHR) to recommend ...
Ashley N. Springer, Leah A. Alicea, Yemi Gafari, Tayler B. Smith, Sheryl Lynch, Amy M. Breman, Jennelle C. Hodge, Victoria M. Pratt, Nicholas R. Powell, Rolf P. Kreutz, Daniel P. Kobold, Michael T. Eadon, Emma M. Tillman, Tyler Shugg, Todd C. Skaar   +14 more
wiley   +1 more source

Assessment of Eptifibatide Clearance by Hemodialysis Using an in vitro System

, 2010
<i>Background/Aims:</i> Eptifibatide is a parenteral glycoprotein IIb-IIIa inhibitor that prevents platelet aggregation. Although contraindicated in dialysis patients due to limited safety and dialysis data, eptifibatide is prescribed in this
Christie A. Green, Elizabeth B. McNeely, Joanna Q. Hudson, Lisa K. Jennings   +3 more
core   +1 more source

Relation of Level of Platelet Inhibition after Eptifibatide with Major Cardiovascular Events in ST-Segment Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Majalah Kardiologi Indonesia, 2015
Background: Eptifibatide, an inhibitor of glycoprotein IIb/IIIa administered as adjunctive therapy to reperfusion therapy Primary PCI in STEMI patients.
Elisa Feriyanti Pakpahan, Sunarya Soerianata, Nur Haryono   +2 more
doaj   +1 more source

High‐throughput screen identifies MAS9 as a novel inhibitor of the C‐type lectin receptor‐2 (CLEC‐2)–podoplanin interaction

British Journal of Pharmacology, Volume 182, Issue 16, Page 3838-3851, August 2025.
Abstract Background and Purpose The C‐type lectin‐like receptor‐2 (CLEC‐2) is a platelet receptor for the endogenous ligand podoplanin. This interaction contributes to several (patho)physiological processes, such as lymphangiogenesis, preservation of blood and lymphatic vessel integrity organ development, and tumour metastasis.
Marcin A. Sowa, Yan Wu, Jan van Groningen, Ying Di, Helma van den Hurk, Johannes A. Eble, Jonathan M. Gibbins, Ángel García, Alice Y. Pollitt   +8 more
wiley   +1 more source

First Phosphonic‐Type Inhibitors and Activity‐Based Probes Specific to the O'nyong‐nyong Virus Capsid Protease

ChemMedChem, Volume 20, Issue 12, June 17, 2025.
The serine capsid protease (CP) catalyzes a crucial process of the alphaviral replication cycle; therefore, it constitutes an interesting therapy target. Herein, the O'nyong‐nyong virus CP profile activity with a specific fluorogenic substrate is analyzed and examines the inhibitory activity of a new series of phosphonic analogs of tryptophan and ...
Karolina Torzyk‐Jurowska, Agnieszka Łupicka‐Słowik, Renata Grzywa, Yuliya Chykunova, Krzysztof Pyrć, Marcin Sieńczyk   +5 more
wiley   +1 more source